A recent meta-analysis revealed that adult NAFLD patients had higher serum resistin levels compared with healthy controls [standardized mean difference (SMD) = 0.522, 95% CI: 0.004–1.040], but there was no obvious difference in serum resistin levels between SS and NASH patients (SMD = 0.15, 95% CI: −0.06 to 0.36) and between SS and controls (SMD = −0.34, 95% CI: −0.91 to 0.23) (41). The gene discussed is RETN; the disease is metabolic dysfunction-associated steatotic liver disease.